Location · Centennial, CO
Clinical trials in Centennial, CO
9 recruiting studies have a site in Centennial, and 0 of them accept healthy volunteers.
9 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Centennial, CO + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma
- Location
- Centennial, CO + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Centennial, CO + 111 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
Phase 1b/2 Study of IV Sarilumab in Adult With RA
Sanofi
- Location
- Centennial, CO + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Centennial, CO + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Ascendis Pharma A/S
- Location
- Centennial, CO + 21 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2/Phase 3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Janssen Research & Development, LLC
- Location
- Centennial, CO + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
ADARx Pharmaceuticals, Inc.
- Location
- Centennial, CO + 14 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Centennial, CO + 111 other US sites
- Eligibility basics
- Ages 18–75